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Abstract
Objectives: South Africa’s national antiretroviral (ARV) treatment program expanded in 2010 to include the nucleoside
reverse transcriptase (RT) inhibitors (NRTI) tenofovir (TDF) for adults and abacavir (ABC) for children. We investigated the
associated changes in genotypic drug resistance patterns in patients with first-line ARV treatment failure since the
introduction of these drugs, and protease inhibitor (PI) resistance patterns in patients who received ritonavir-boosted
lopinavir (LPV/r)-containing therapy.
Methods: We analysed ARV treatment histories and HIV-1 RT and protease mutations in plasma samples submitted to the
Tygerberg Academic Hospital National Health Service Laboratory.
Results: Between 2006 and 2012, 1,667 plasma samples from 1,416 ARV-treated patients, including 588 children and infants,
were submitted for genotypic resistance testing. Compared with 720 recipients of a d4T or AZT-containing first-line
regimen, the 153 recipients of a TDF-containing first-line regimen were more likely to have the RT mutations K65R (46% vs
4.0%; p,0.001), Y115F (10% vs. 0.6%; p,0.001), L74VI (8.5% vs. 1.8%; p,0.001), and K70EGQ (7.8% vs. 0.4%) and recipients
of an ABC-containing first-line regimen were more likely to have K65R (17% vs 4.0%; p,0.001), Y115F (30% vs 0.6%;
p,0.001), and L74VI (56% vs 1.8%; p,0.001). Among the 490 LPV/r recipients, 55 (11%) had $1 LPV-resistance mutations
including 45 (9.6%) with intermediate or high-level LPV resistance. Low (20 patients) and intermediate (3 patients) darunavir
(DRV) cross resistance was present in 23 (4.6%) patients.
Conclusions: Among patients experiencing virological failure on a first-line regimen containing two NRTI plus one NNRTI,
the use of TDF in adults and ABC in children was associated with an increase in four major non- thymidine analogue
mutations. In a minority of patients, LPV/r-use was associated with intermediate or high-level LPV resistance with
predominantly low-level DRV cross-resistance.
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Introduction
The South African National Government began providing
antiretroviral (ARV) therapy to the public sector in 2004. Until
2009, standard first-line regimens were stavudine (d4T) plus
lamivudine (3TC) combined with a third agent: a non-nucleoside
reverse transcriptase (RT) inhibitor (NNRTI) in adults and older
children or ritonavir-boosted lopinavir (LPV/r) in young children
who had received nevirapine (NVP) for prevention of mother-to-
child transmission (PMTCT). In 2010, when the South African
guidelines were aligned to updated World Health Organization
guidelines, D4T was replaced by tenofovir disoproxil fumarate
(TDF) in adults and older children and abacavir (ABC) in younger
children, respectively. Adults beginning ARV treatment increas-
ingly received TDF rather than d4T for first-line therapy and
children increasingly received ABC rather than d4T [1,2]. The
2004 and 2010 antiretroviral therapy guidelines for adults and
children are summarised in Table 1. Although there are ample
published data on antiretroviral resistance outcomes of D4T-based
regimens in non-subtype B HIV-1 populations, data on the
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resistance patterns after failure of TDF and ABC-based regimens
are limited [3]. Here we examine the effect of ARV usage changes
on the patterns of genotypic resistance mutations and their
implications for ARV cross-resistance in patients with ARV
treatment failure, in a population where HIV-1 subtype C
predominates.
Methods
Study Population
Since 2006, the National Health Laboratory Service (NHLS)
virology laboratory at Tygerberg Academic Hospital has provided
ARV genotypic resistance testing for public sector clinics in the
Western Cape, Gauteng and Eastern Cape provinces, as allowed
by individual clinic or hospital budgets or external funding.
Samples received between 2006 and 2012 from children (age
below 15 years) and adults with virological failure on a standard
first- or second-line regimen for whom demographic and ARV
treatment information were provided by their physicians were
included in the study. The Stellenbosch University Health
Research Ethics Committee approved the study, reference
number: N11/09/274.
The treatment histories provided by physicians were assessed in
light of the contemporaneous ARV treatment policies in South
Africa. Until 2010, the standard adult first-line regimens were d4T
combined with 3TC plus either NVP or efavirenz (EFV).
Zidovudine (AZT) was often used as a substitute for d4T in case
of toxicity. Children younger than three years were generally
treated with a boosted lopinavir (LPV/r)-containing first-line
regimen under the assumption that a high proportion had been
infected with a virus exposed to NNRTI selection pressure as a
result of maternal NVP therapy. Initially standard second-line
therapy for adults consisted of AZT combined with didanosine
(DDI) and LPV/r [4]. Starting in 2010, second-line therapy
consisted of 3TC and LPV/r combined with either TDF or AZT,
depending on whether patients had failed a thymidine analogue
(D4T or AZT)-containing or a TDF-containing first-line regimen.
Second-line therapy for children who had started on LPV/r
initially included NVP or EFV in combination with two NRTIs.
However, according to the 2010 revised guidelines, expert advice
had to be obtained for children experiencing failure of a first-line
LPV/r regimen, because such failure is mostly due to poor
adherence rather than resistance. In some patients, a second-line
regimen included three rather than two NRTIs. In adults and
children receiving rifampicin concurrently with LPV/r, additional
ritonavir was often added, according to therapy guidelines, to
increase LPV levels.
In accordance with the revised recommendations, TDF or ABC
replaced d4T in a number of patients, who experienced adverse
effects, but this was not always noted; therefore a subset of patients
recorded as receiving TDF or ABC in combination with 3TC and
either NVP or EFV may have previously received d4T.
Laboratory monitoring and detection of failure: The recom-
mended frequency of viral load testing and CD4 testing after
initiation of ARV therapy, was six monthly, until the testing
frequency was reduced, in 2010, to testing after six months, 12
months and then annually. The definition of virologic failure in
adults and adolescents, according to the original South African
National Guidelines was repeated HIV viral load measures above
5000 copies/ml. Virological failure in children was defined as
rebound of viral load to baseline, and switching to a second-line
paediatric regimen was otherwise based on clinical and immuno-
logical failure [4]. The definition of virological failure was
amended in the 2010 guidelines (Table 1), with virologic failure
defined as repeated HIV viral load measures above 1000 copies/
ml [1,2]. However, many clinicians switched patients at a
threshold of 1000 copies/ml prior to the publication of the 2010
revised guidelines, based on interim communications, localised
guidelines and observational studies that detected resistance at
lower viral loads.
Genotypic Resistance Testing
Standard dideoxynucleotide terminator sequencing was per-
formed using an in-house protocol [5] that amplifies HIV-1
Table 1. South African National Antiretroviral Therapy Guidelines 2004 and 2010.
Guideline date 2004 2010
Adults and Adolescents
First-line therapy 1D4T, 3TC, 2EFV/NVP Newly initiated patients: 3TDF, 3TC/FTC, 2EFV/NVP
Definition of virologic failure Repeated HIV-1 RNA load .5000 copies/ml Repeated HIV-1 RNA load .1000 copies/ml
Second-line therapy AZT, DDI, LPV/r AZT, 3TC, LPV/r (or TDF, 3TC, LPV/r in case of failure of a D4T
or AZT containing regimen)
Children #3 years #3 kg
First-line therapy D4T, 3TC, LPV/r ABC, 3TC, LPV/r
Definition of virologic failure Rebound of HIV-1 RNA load to baseline Repeated HIV-1 RNA load .1000 copies/ml
Second-line therapy AZT, DDI, NVP 4Refer for expert opinion
Children .3 years or .10 kg
First-line therapy D4T, 3TC, EFV ABC, 3TC, EFV
Definition of virologic failure Rebound of HIV-1 RNA load to baseline Repeated HIV-1 RNA load .1000 copies/ml
Second-line therapy AZT, DDI, LPV/r AZT,DDI, LPV/r
1D4T could be substituted for AZT in case of toxicity; EFV or NVP chosen dependent on pregnancy risk, EFV chosen when patients receive concurrent rifampicin for
tuberculosis. Over time a gradual move to prefer EFV as data suggest that risk to foetus is small. 3TDF replaced by AZT if contra-indicated (e.g. kidney disease). 4Based
on data that most children with virologic failuire of a LPV/r first-line regimen have inadequate adherence and no LPV associated resistance, blanket switching is not
indicated.
Patients who were still on D4T by the time of the 2010 regimen guidelines could remain on D4T if they did not experience toxicity. However, practically the threshold
for switching for lypodystrophy or other side effects is generally low.
doi:10.1371/journal.pone.0067188.t001
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nucleotide positions 2250 to 4229 (HXB2 numbering), spanning
the complete PR gene and RT codons 1 to 262. PCR reactions
included reagent blanks and, in addition, after each sequencing
run, a phylogenetic tree was drawn using all patient sequences and
a positive control, included in the run, to enable us to identify
possible contamination. Sequences were analysed using the
Stanford University HIV Drug Resistance Database (HIVDB)
Sierra Webservice (http://hivdb.stanford.edu/pages/webservices).
HIV-1 subtyping was performed using the Rega Subtyping Tool
[6]. Mutations were defined as amino acid differences from the
wild-type consensus HIV-1 B sequence.
The following non-polymorphic ARV-selected mutations were
classified as drug resistance mutations (DRM): (i) the NRTI
resistance mutations M41L, A62V, K65RN, D67NG, T69D, T69
insertions, T69 deletion, K70REGQ, L74VI, V75MT, F77L,
Y115F, F116Y, Q151M, M184VI, L210W, T215YFSDCIV, and
K219QENR; (ii) the NNRTI resistance mutations A98G, L100I,
K101EPH, K103NS, V106MA, E138KGQ, V179DEFT,
Y181CIV, Y188LCH, G190ASEQ, H221Y, P225H, F227LC,
M230L, and K238T; and (iii) the PI resistance mutations L10F,
V11I, L23I, L24I, D30N, L33F, M46IL, I47VA, G48VM, I50V,
I54VMLATS, G73STCA, T74P, L76V, V82ATFSCML, I84V,
N88DS, L89V, L90M.
Different RT mutations at the same residue were pooled,
including the NRTI-resistance mutations D67NG, K70EGQ,
L74VI, M184VI, T215YF, K219QE and the NNRTI-resistance
mutations K101EH, K103NS, Y188LCH, and G190ASEQ.
Thymidine analogue mutations (TAMs) were defined as M41L,
D67NG, K70R, L210W, T215YF, and K219QE. The Q151M
complex of mutations was defined as Q151M alone or in
combination with one or more of the following mutations:
A62V, V75I, F77L, and F116Y. Sequences that terminated
between positions 219 and 229 were included in the analysis of
NRTI mutation frequency but not in the analysis of NNRTI
mutation frequency. The following protease mutations were
considered LPV/r-resistance mutations: L10F, L24I, V32I,
L33F, M46IL, I47A, I50V, I54MLV, L76V, V82ATSFMC,
I84V, L89V, L90M.
When more than one sample was received while a patient
received a particular regimen, the sample containing the most
drug resistance was chosen, which equalled the cumulative
resistance in almost all cases.
Statistical Analysis
We used the Fisher Exact statistic to compare the proportions of
NRTI- and NNRTI-resistance proportions in patients receiving
different first-line regimens. Although no explicit correction for
multiple comparisons was made, only those differences with a p-
value ,0.01 were noted.
Results
ARV Treatment Regimens
Overall, 1,515 patients had samples submitted for HIV-1
genotypic resistance testing between May 2006 and July 2012.
Ninety-four percent (1,416 of 1,515) of patients had a physician-
provided ARV treatment history consistent with a standard first-
or second-line regimen. Two hundred patients had more than one
sample submitted for genotypic resistance testing, including 147
patients who had samples obtained while on different ARV
treatment regimens.
Table 2 shows the demographics and ARV treatment histories
of these 1,416 patients. Forty-four percent of patients were 15
years or younger at the time of their first sample; 58% were
female. The most commonly received NRTI combinations were
d4T/3TC (47% of patients), TDF/3TC (13%), AZT/3TC (10%),
AZT/DDI (8%), and ABC/3TC (6%). Fifty seven percent of
patients had received EFV and seven percent had received NVP.
LPV/r was received by 35% of patients including six percent of
patients who received a non-standard regimen combining LPV/r
and EFV. Ten percent of patients had received a regimen with
three NRTIs (the largest number of these combined with an
NNRTI).
TDF use in adults increased from 3% between 2006 and 2009
to 37% between 2010 and 2012 and ABC use from 2% to 6%. In
children, ABC use increased from 13% between 2006 and 2009 to
29% between 2010 and 2012. The increase in TDF and ABC use
was associated with a concurrent decrease in d4T, DDI and AZT
Table 2. Demographic and Antiretroviral Treatments of 1,416
Patients Undergoing HIV-1 Genotypic Resistance Testing,
2006–2012.
Number Percent
Gender Female 821 58
Age* #5 210 15
6 to 10 211 15
11 to 15 200 14
16 to 20 62 4
21 to 30 134 10
31 to 40 331 23
41 to 50 201 14
$51 67 5
Year of sample* 2006 29 2
2007 127 9
2008 119 8
2009 228 16
2010 312 22
2011 396 28
2012 205 15
Number of samples per patient 1 1216 86
2 154 11
$3 46 3
NRTIs d4T/3TC 664 47
TDF/3TC 186 13
AZT/3TC 138 10
AZT/DDI 122 8
ABC/3TC 82 6
3 NRTIs 140 10
Misc 84 6
NNRTI/PIs{ EFV 810 57
LPV/r 413 29
NVP 94 7
EFV, LPV/r 86 6
Footnote: *For patients with more than one sample, the age of the patient at
the time of the first sample and the year and treatment of the last sample were
used.
{The patients receiving EFV and LPV/r included those receiving these ARVs as
part of separate regimens and those receiving these as part of salvage therapy.
Misc: Miscellaneous refers to other (rare) NRTI combinations.
doi:10.1371/journal.pone.0067188.t002
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use. Overall, in both age groups, d4T, AZT, and DDI had been
used in 65%, 32%, and 20% of patients between 2006 and 2009
and in 45%, 26%, and 14% of patients between 2010 and 2012.
Among the 569 adults receiving first-line regimens 313 (55%)
received d4T plus 3TC, 90 (16%) AZT plus 3TC, 153 (27%) TDF
plus 3TC, 13 (2%) received ABC plus 3TC. Four hundred and
ninety five (87%) received EFV and 74 (13%) NVP. Among the
508 children and infants receiving first-line therapy, 421 (83%)
received D4T and 3TC, 65 (13%) ABC plus 3TC and 22 (4%)
received AZT plus 3TC. Three hundred and forty one (67%)
received EFV, 150 (30%) received LPV/r and 17 (3%) received
NVP. Among the 290 adults receiving second-line regimens, the
most commonly used regimens included: 126 (43%) receiving
AZT plus DDI, 43 (15%) receiving AZT plus 3TC, 37 (13%)
receiving TDF plus 3TC/FTC, and 68 (23%) receiving three or
more NRTIs, with the rest receiving rare combinations, in each
case combined with LPV/r. A wide variety of second-line
regimens were used in children and infants, due to the need of
expert advice before changing the regimen.
HIV-1 RT and Protease Sequences
HIV-1 subtype C sequences comprised 98.2% of patient
sequences. The remaining virus subtypes included A (0.9%), B
(0.1%), BC recombinants (0.6%) and miscellaneous subtypes and
recombinant forms (0.2%). The median uncorrected genetic
distance (Hamming distance) for sequences from different patients
was 7.4% (95% range: 5.4% to 11.1%; Figure 1). Fourty-one
patients (2.7% of 1,511) had a virus sequence with a genetic
distance ,2.0% from another virus sequence; twenty patients
(1.3%) had a virus sequence with a genetic distance ,1.0% from
another virus sequence. The median genetic distance between
sequences from the same patient was 1.5% (95% range: 0.1% to
7.5%; Figure 2). The GenBank accession numbers of the
sequences are KC422792–KC424425.
Genotypic ARV-resistance during First-line Dual NRTI/
NNRTI Treatment
NRTI-resistance mutations. Table 3 shows the proportions
of the most common NRTI-resistance mutations in the 927 adults
and children receiving a first-line dual NRTI plus NNRTI
regimen. Three mutations – K65R, L74VI, and Y115F – occurred
in a higher proportion of patients receiving TDF and ABC
compared to patients receiving d4T or AZT. K70EG occurred in
a higher proportion of patients receiving TDF compared to
patients receiving d4T or AZT.
K65R occurred in 70/153 (45.8%) patients failing ARV and
receiving TDF and in 9/54 (16.7%) patients receiving ABC
compared with 20/720 (2.8%) patients receiving d4T or AZT
(p,0.001 for both TDF and ABC). L74VI occurred in 13/153
(8.5%) patients receiving TDF and 30/54 (55.6%) receiving ABC
compared with 1.8% receiving d4T or AZT (p,0.001 for both
TDF and ABC). Y115F occurred in 16/153 (10.5%) patients
receiving TDF and 16/54 (29.6%) receiving ABC compared with
4/720 (0.6%) patients receiving d4T or AZT (p,0.001; for both
TDF and ABC). K70QEG occurred in 12/153 (7.8%) patients
receiving TDF compared with 3/720(0.4%) receiving d4T or AZT
(p,0.001).
TAMs occurred in a higher proportion of patients receiving an
AZT-containing regimen than in patients receiving a TDF- or
ABC-containing regimen (39% vs. 18%; p,0.001). However,
there was no difference in the proportion of patients with TAMs
between those receiving a d4T-containing regimen compared with
those receiving a TDF- or ABC-containing regimen (16% vs.
18%). M184V/I (82.8% vs. 72%; p = 0.006) occurred in a
somewhat higher proportion of patients receiving a d4T- or
AZT-based first-line regimen than an ABC- or TDF-based
regimen.
K65R occurred in a higher proportion of patients receiving
TDF plus 3TC plus NVP than TDF plus 3TC plus EFV (16/
20; 80% vs. 54/133; p = 0.001) but there were otherwise no
significant differences in the proportions of NRTI-resistance
mutations between the 91 patients receiving an NVP-containing
regimen compared with the 836 receiving an EFV-containing
regimen.
Additional NRTI resistance mutations not shown in Table 3
included (i) A62V, which occurred more commonly in patients
receiving TDF (19/153; 12.4%) than in those receiving AZT, d4T,
or ABC (36/774, 4.7%; p,0.001); and among TDF-recipients,
A62V occurred more commonly in samples with K65R plus
M184V (14/39, 35.9%) than in samples with M184V alone (4/50,
8%; p,0.001), K65R alone (1/31, 3.2%; p,0.001), or neither
K65R nor M184V (0/33, 0%; p,0.001). (ii) K65N, which
occurred in one patient receiving TDF; (iii) T69D, V75M, and
V75T, which occurred in 1.3%, 2.5%, and 0.3% respectively; (iv)
T215I occurred in 1.4% of patients; and (v) K219R and K219N,
occurred in 1.6% and 0.9% respectively.
An analysis of the complete set of RT sequences, identified two
novel, possibly subtype C-associated, NRTI mutations. T165L, a
nonpolymorphic mutation previously reported to be associated
with NRTI therapy occurred in 1.6% (22) of patients, a proportion
similar to the 1.3% found in the ,3,600 RTI-experienced subtype
C-infected patients in HIVDB but significantly higher than the
0.4% found in the ,25,000 RTI-experienced non-subtype C-
infected patients in HIVDB. S68N occurred in 1.4% (20) of
patients, a proportion higher than the 0.1% and 0.3% previously
found in the subtype C and non-subtype C RTI-experienced
patients in HIVDB. Of note, 18 of the 20 patients with this
mutation also had K65R.
NNRTI-resistance mutations. Table 4 shows the propor-
tions of NNRTI-resistance mutations among the 887 adults and
children receiving a first-line dual NRTI/NNRTI containing
regimen. A higher proportion of patients receiving EFV (37% of
801) had viruses with V106M compared with those receiving NVP
(12% of 86; p,0.001). A higher proportion of patients receiving
NVP (41% of 86) had viruses with Y181C compared with those
receiving EFV (5% of 801; p,0.001). Among the patients
receiving EFV, L100I occurred in a higher proportion of the 53
patients receiving ABC/3TC (23%) compared with the remaining
748 patients (3.1%; p,0.001) and Y181C occurred in a higher
proportion of the 127 patients receiving TDF/3TC (18%)
compared with the remaining 674 patients (2.5%; p,0.001).
Y188C, a mutation previously reported in 0.1% of non-subtype C
sequences occurred in 1.5% (21) patients in this study. In 19 of 21
patients, Y188C occurred in combination with V106M.
Additional NNRTI-resistance mutations not shown in Table 4
included (i) A98G, which occurred in 3.3% of NNRTI-treated
patients; (ii) V106A, which occurred in 0.6% of NNRTI-treated
patients; (iii) E138G/Q, which occurred in 0.9% and 0.9% of
patients, respectively; (iv) V179D/E/T/F, which occurred in
8.5%, 0.7%, 0.5%, and 0% of NNRTI-treated patients respec-
tively; (v) Y181I/V, which occurred in one and no patient,
respectively; (vi) H221Y, which occurred in 5.9% of EFV-treated
and 9.3% of NVP-treated patients (p,0.001); (vii) P225H, which
occurred in 13.6% of EFV-treated and 5.8% of NVP-treated
patients (p = 0.01); and (viii) F227C, which occurred in three
patients; and (ix) K238T, which occurred in 2.3% of NNRTI-
treated patients.
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Figure 1. The distribution of uncorrected genetic distance between sequences of different patients. The median uncorrected genetic
distance for sequences from different patients was 7.4% (95% range: 5.4% to 11.1%).
doi:10.1371/journal.pone.0067188.g001
Figure 2. The distribution of uncorrected genetic distance between the sequences from the same patient. The median genetic distance
between sequences from the same patient was 1.5% (95% range: 0.1% to 7.5%).
doi:10.1371/journal.pone.0067188.g002
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PI-resistance Mutations in Patients Receiving LPV/r
Of the 490 patients who received an LPV/r-containing
regimen, 55 (11.2%) had plasma virus samples with one or more
LPV-resistance mutations. These 55 plasma virus samples
comprised 36 distinct patterns of LPV-resistance mutations
(Table 5). Overall, the genotype predicted intermediate or high-
level LPV resistance in 45 patients, intermediate or high-level
ATV resistance in 36 and DRV resistance in 23 (intermediate
(n = 3) or low-level (n = 20)) patients. Because 18 of the 48 patients
with LPV resistance also had NRTI and NNRTI resistance, the
overall proportion of patients with three-class resistance was 1.3%
(18/1416).
Table 3. Nucleoside RT Inhibitor (NRTI) Resistance Mutations: Percent Occurrence in Patients Treated with Dual NRTI plus
Nonnucleoside RT Inhibitor (NNRTI) First-Line Antiretroviral (ARV) Regimens.
ARV Regimen No.* 184{VI Thymidine Analogue Mutations (TAMs) Discriminatory Mutations
NRTIs NNRTI 41 67 70 210 215 219 69 65 69 70 74 115 151
(%) L NG R W YF QE ins R del EQG VI F M
(%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
Thymidine analog-based regimens
d4T/3TC EFV 573 82 1.8 9.6 5.1 0.2 3.5 3.5 0.2 3.3 0.5 0.5 1.9 0.7 0.5
NVP 42 88.1 9.5 16.7 2.4 2.4 19 4.8 0 0 0 0 0 0 0
AZT/3TC EFV 76 76.3 7.9 27.6 25 5.3 26.3 19.7 0 1.3 0 0 2.6 0 0
NVP 29 86.2 0 27.6 27.6 0 13.8 17.2 0 0 0 0 0 0 0
Totals1: 720 81.9* 2.8 12.6 7.9 0.8 7.2* 5.8 0.1 2.8** 0.4 0.4** 1.8** 0.6** 0.4
Tenofovir (TDF) and abacavir (ABC)-based regimens
TDF/3TC EFV 133 63.9 0.8 13.5 6 0 3.0 9.8 0 40.6 1.5 8.3 8.3 10.5 1.5
NVP 20 90 5.0 5.0 0 0 5.0 5.0 0 80 5.0 5 10 10 5.0
ABC/3TC EFV 54 81.5 1.9 7.4 0 0 0 1.9 0 16.7 0 0 55.6 29.6 1.85
Totals1: 207 71* 1.5 11.1 3.9 0 2.4* 7.2 0 38.2** 1.5 5.8** 20.8** 15.5** 1.9
Footnote: *No.: Number of patients receiving first-line therapy with the ARV regimen indicated in the first two columns.
{Although M184V/I is a discriminatory mutation it is shown separately because it is the single most common mutation.
1The proportion of individuals receiving a thymidine analog (d4T or AZT) or non-thymidine analog (TDF or ABC) based regimen having the indicated mutation.
Mutations for which there were statistically significant differences between these proportions are in bold, *p#0.01, **p#0.001.
doi:10.1371/journal.pone.0067188.t003
Table 4. Nonnucleoside RT Inhibitor (NNRTI) Resistance Mutations: Percent Occurrence in Patients Treated with Dual nucleoside
RT inhibitor (NRTI) plus NNRTI First Line Antiretroviral (ARV) Regimens.
ARV Regimen No.* 100 101 101 103 106 138 181 188 190 230
NNRTI NRTI L P EH NS M K C LCH ASEQ L
(%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
Efavirenz (EFV)-containing regimens
EFV d4T/3TC 548 3.3 1.5 11.7 56.4 35.2 1.1 2.4 9.9 15.1 6.9
AZT/3TC 73 1.4 1.4 5.5 49.3 27.4 2.7 1.4 12.3 9.6 9.6
TDF/3TC 127 3.1 1.6 15.7 32.3 48.8 0 18.1 9.4 21.3 4.7
ABC/3TC 53 22.6 1.9 11.3 56.6 37.7 3.8 5.7 7.5 11.3 1.9
Totals{: 801 4.4 1.5 11.7 51.9 36.8** 1.2 5.0** 9.9 15.4 6.5
Nevirapine (NVP)-containing regimens
NVP d4T/3TC 40 0 2.5 22.5 52.5 15 0 37.5 7.5 10 5
AZT/3TC 27 0 0 25.9 25.9 14.8 0 25.9 3.7 29.6 11.1
TDF/3TC 19 0 5.3 10.5 36.8 0 0 68.4 0 31.6 10.5
Totals{: 86 0 2.3 20.9 40.7 11.6** 0 40.7** 4.7 20.9 8.1
Footnote: *No.: Number of patients receiving first-line therapy with the ARV regimen indicated in the first two columns.
{The proportion of individuals treated with NVP or EFV. Mutations for which there were statistically significant differences according to the NNRTI received: **p#0.001.
Fewer sequences were included in table 4 than in table 3 as sequences that terminated between positions 219 and 229 were excluded from the numerator and
denominator for NNRTI mutation statistics.
doi:10.1371/journal.pone.0067188.t004
Genotypic HIV-1 Drug Resistance in South Africa
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e67188
Discussion
In the nine years since the start of the South African National
ARV Treatment Program, therapy has evolved in accordance with
WHO ARV treatment recommendations. TDF and ABC have
increasingly been used in place of d4T and AZT in patients
receiving first-line therapy and the number of patients requiring
second-line therapy with LPV/r has gradually increased [2]. In
this study, we assessed the effect of the expanded use of TDF and
ABC on the patterns of NRTI resistance in patients experiencing
first-line virological failure and the extent of PI cross-resistance
among patients receiving LPV/r.
The data presented in this study substantially increases the
number of publicly available sequences, as of April 2013, from
ARV-treated subtype C infected patients. The subtype C RT
sequences from 1,398 NRTI 6 NNRTI-treated patients repre-
sents nearly 40% of the ,3,600 of such patients in HIVDB. The
subtype C PR sequences from 486 LPV/r-treated patients more
than double the number of all subtype C-infected patients in
HIVDB.
Among patients with virological failure on a first-line dual
NRTI plus NNRTI regimen, a higher proportion of those who
received TDF and/or ABC had the non-TAMs K65R, K70EQG,
L74VI, and Y115F compared with those receiving d4T or AZT.
M184V, the most common NRTI-resistance mutation, occurred
in a significantly but only modestly higher proportion of patients
receiving an AZT- or d4T-containing regimen compared with
those receiving a TDF- or ABC-containing regimen.
With the exception of infrequent mutations at codons 67 and
219, TAMs rarely occurred in patients receiving ABC plus 3TC-
or TDF plus 3TC-containing first-line regimens. The fact that
21% of TDF recipients and 10% of ABC recipients had TAMs is
therefore consistent with the substitution of these NRTIs for
managing d4T toxicity. Such single drug switches in patients
without documented virological suppression is a likely explanation
for the higher than expected frequency of TAMs in TDF and ABC
recipients.
The high proportion of non-TAMs in patients receiving first-
line TDF- and ABC-containing regimens is a striking example of
HIV-19s ability to evolve under different selection pressures. The
high proportion of non-TAMs is also of concern in that the
number of ARV-resistance mutations developing during virolog-
ical failure is often related to the duration of failure. Indeed, the
risk of K65R was significantly higher in the 20 patients receiving
TDF plus 3TC plus NVP compared to the 133 patients receiving
TDF plus 3TC plus EFV, a finding consistent with previous
reports questioning the efficacy of TDF plus 3TC plus NVP [7,8].
As our study was a laboratory-based study, we were not able to
evaluate the response to therapy with TDF- and ABC-containing
regimens. Indeed, patients in this study who were treated with an
initial TDF- or ABC-containing regimen or with TDF or ABC as a
substitute for d4T may have had more advanced HIV-1 disease.
However, a recent retrospective South African study of 585
patients receiving first-line therapy with TDF and 3TC plus an
NNRTI was particularly informative [3]. It reported that despite a
low prevalence of virological failure of six percent, the median
time to presentation for those with virological failure was only six
months. Whether rapid failure occurred more commonly among
those receiving TDF plus 3TC plus NVP as compared to TDF
plus 3TC plus EFV was not indicated. As in our study, M184V,
K65R, and Y115F were the most common major NRTI
mutations.
The distribution of NNRTI resistance mutations was consistent
with previous studies: V106M was significantly more common
Table 5. Protease Inhibitor (PI)-Resistance Mutation Patterns
in Viruses From Patients Receiving Lopinavir/r and their
Predicted Effect on PI Cross Resistance*.
No.
Mut Mutation List{
Num
Pts LPV1 ATV1 DRV1
1 L10F 1 5 0 0
L33F 1 5 5 5
M46L 1 10 10 0
I47A" 1 60 70" 10
I54V 1 10 15 0
L76V 1 30 0 20
V82A 1 25 15 0
I84V 1 15 45 10
L90M 1 10 20 0
2 I54V, V82A 6 35 35 0
L10F, V82A 4 30 15 0
M46I, L76V 2 50 7.5 20
I54V, I84V 1 25 55 10
M46I, V82A 1 35 30 0
M46I, I50V 1 30 10 20
V32I, I47A 1 .60 20 30
3 M46I, I54V, V82A 3 55 50 0
I54V, L76V, V82A 2 .60 45.5 20
L24I, V32I, I47A 1 .60 25 30
L10F, L76V, V82A 1 60 15 20
4 M46I, I54V, L76V, V82A 3 .60 .60 20
M46I, I50V, I54V, V82A" 2 .60 .60" 20
L10F, M46I, I54V, V82A 2 .60 60* 20
L10F, I54V, I84V, L89V" 1 35 .60" 15
L10F, L33F, I54V, V82A 1 55 45 5
L10F, L24I, I54V, V82A 1 .60 45 0
5 L10F, M46I, I54V, L76V, V82A 4 .60 55 20
L10F, M46L, I54V, L76V, V82A 1 .60 55 20
L10F, M46I, I54V, V82A, I84V 1 50 .60 10
L10F, M46I, I54V, L76V, I84V 1 .60 60 30
L10F, L24I, L33F, I54V, V82A 1 .60 55 5
L10F, L33F, I54V, L76V, V82A 1 .60 40 25
6 L10F, L24I, L33F, M46I, I54V, V82A 1 .60 .60 5
L10F, L24I, L33F, M46L, I54V, V82A 1 .60 .60 5
L10F, L33F, M46I, I54V, V82A, L90M 1 .60 .60 5
L10F, L33F, M46I, I50V, I54V, V82A 1 .60 .60 25
7 L10F, L24I, L33F, M46I, I54V, L76V, V82A 1 .60 .60 25
Footnote: *36 patterns of PI-resistance mutations from 55 patients.
{PI-resistance mutations included L10F, L24I, L33F, V32I, M46I/L, I50V, I54V, L76V,
V82A, I84V, L89V, and L90M. (D30N, I47V, G48V, I50L, I54L/M/T/A/S, and V82T/S/F did
not occur in this dataset). V82M and V82C occurred in 2 patients and were
represented by V82A. The accessory mutations L10I/V and A71V/T occurred
commonly but are not shown. The mutations V11I, F53L, G73S, T74P, N83D, and
N88S each occurred in 1 to 3 patients and are also not shown.
1Predicted reduced susceptibility to lopinavir/r (LPV), atazanavir/r (ATV), and
darunavir/r (DRV) according to the HIVDB drug-resistance interpretation system.
Scores $60 indicate high-level resistance; scores between 30 and 59, intermediate
resistance; scores between 15 and 29, low-level resistance.
"One of more samples with this pattern of study-defined LPVr mutations had
additional PI-resistancemutations that influenced the extent of ATVr cross resistance.
For example, the sample with I47A also had the mutation N88S which is associated
with high-level ATVr resistance.
doi:10.1371/journal.pone.0067188.t005
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among patients receiving EFV and Y181C was significantly more
common among patients receiving NVP [9,10,11,12]. The
statistical associations of Y181C with TDF and of L100I with
ABC have not previously been reported. The former association is
surprising because Y181C increases TDF susceptibility [13,14].
The presence of L74V in patients who failed TDF-based regimen
was also surprising as L74V increased TDF susceptibility in vitro
[14,15].
The 11% prevalence of LPV/r resistance among patients with
virological failure on an LPV/r containing regimen is consistent
with studies from the U.K. [16] and from South Africa [17]. This
finding suggests that in patients with virological failure on an
LPV/r-containing regimen, genotypic resistance testing can
distinguish those who may respond to improved adherence from
those who require a change in therapy. The development of just
low level DRV resistance in about one-half of the patients with
LPV resistance, or rarely intermediate resistance, suggests that
DRV may be a valuable component of a third-line antiretroviral
regimen.
In conclusion, changes in HIV treatment practices are greatly
influencing the genotypic patterns of ARV resistance and cross-
resistance in patients experiencing first-line ARV treatment
failure. Indeed a high proportion of patients receiving TDF or
ABC had non-TAMs that were uncommonly observed in patients
receiving AZT or d4T. Although TDF and ABC are more potent
and less toxic HIV-1 inhibitors than d4T and AZT, the impact of
their widespread introduction in South Africa requires ongoing
monitoring to ensure that the efficacy of first-line therapy is not
compromised, and to identify optimal second-line regimens.
Currently over 1.7 million patients are on ARV therapy in
South Africa and with the anticipated increased complexity of
regimens as therapy history increases, an increased need for
resistance testing is expected. Importantly, in order to inform
national and international policy makers, genotypic data and its
associated treatment regimen should be made available in public
databases [18].
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